Terms: = Skin cancer AND CTNNB1, P35222, 1499, ENSG00000168036, CTNNB AND Treatment
17 results:
1. Distinct presentation of melanoma in Black patients may inform strategies to improve outcomes.
Steadman JA; Glasgow AE; Neequaye NN; Habermann EB; Hieken TJ
J Surg Oncol; 2024 May; 129(6):1041-1050. PubMed ID: 38436625
[TBL] [Abstract] [Full Text] [Related]
2. Targeted next-generation sequencing of Japanese patients with sinonasal mucosal melanomas identifies frequent NRAS and ctnnb1 mutations.
Tsushima N; Kano S; Hatanaka KC; Suzuki T; Hamada S; Idogawa H; Nakamaru Y; Suzuki M; Hatanaka Y; Homma A
Auris Nasus Larynx; 2024 Apr; 51(2):313-319. PubMed ID: 37953090
[TBL] [Abstract] [Full Text] [Related]
3. Variable Genomic Landscapes of Advanced Melanomas with Heavy Pigmentation.
Huang RSP; Tse JY; Harries L; Graf RP; Lin DI; Murugesan K; Hiemenz MC; Parimi V; Janovitz T; Decker B; Severson E; Levy MA; Ramkissoon SH; Elvin JA; Ross JS; Williams EA
Oncologist; 2022 Aug; 27(8):655-662. PubMed ID: 35552752
[TBL] [Abstract] [Full Text] [Related]
4. Detection of Melanogenesis and Anti-Apoptosis-Associated Melanoma Factors: Array CGH and PPI Mapping Integrating Study.
Yin SJ; Qian GY; Yang JM; Lee J; Park YD
Protein Pept Lett; 2021; 28(12):1408-1424. PubMed ID: 34749602
[TBL] [Abstract] [Full Text] [Related]
5. Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy.
Olbryt M; Pigłowski W; Rajczykowski M; Pfeifer A; Student S; Fiszer-Kierzkowska A
Target Oncol; 2020 Feb; 15(1):101-113. PubMed ID: 31980996
[TBL] [Abstract] [Full Text] [Related]
6. Prospective Molecular Profiling of Circulating Tumor Cells from Patients with Melanoma Receiving Combinatorial Immunotherapy.
Lin SY; Chang SC; Lam S; Irene Ramos R; Tran K; Ohe S; Salomon MP; Bhagat AAS; Teck Lim C; Fischer TD; Foshag LJ; Boley CL; O'Day SJ; Hoon DSB
Clin Chem; 2020 Jan; 66(1):169-177. PubMed ID: 31672856
[TBL] [Abstract] [Full Text] [Related]
7. Arotinoid trometamol inhibits arsenic trioxide-stimulated keratinocyte proliferation via the Wnt, Shh, and bone morphogenetic protein signaling pathways.
Zhou X; Yan L; Bu XL; Xu XG; Bi XL; Gu J
J Biol Regul Homeost Agents; 2019; 33(3):731-743. PubMed ID: 31232011
[TBL] [Abstract] [Full Text] [Related]
8. Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion.
McEvoy CR; Xu H; Smith K; Etemadmoghadam D; San Leong H; Choong DY; Byrne DJ; Iravani A; Beck S; Mileshkin L; Tothill RW; Bowtell DD; Bates BM; Nastevski V; Browning J; Bell AH; Khoo C; Desai J; Fellowes AP; Fox SB; Prall OW
J Clin Invest; 2019 May; 129(5):1940-1945. PubMed ID: 30835257
[TBL] [Abstract] [Full Text] [Related]
9. Interaction of molecular alterations with immune response in melanoma.
Szczepaniak Sloane RA; Gopalakrishnan V; Reddy SM; Zhang X; Reuben A; Wargo JA
Cancer; 2017 Jun; 123(S11):2130-2142. PubMed ID: 28543700
[TBL] [Abstract] [Full Text] [Related]
10. Emergence of ctnnb1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma.
Cho J; Kim SY; Kim YJ; Sim MH; Kim ST; Kim NKD; Kim K; Park W; Kim JH; Jang KT; Lee J
Clin Transl Oncol; 2017 Oct; 19(10):1247-1252. PubMed ID: 28421416
[TBL] [Abstract] [Full Text] [Related]
11. Biodegradable nanocomplex from hyaluronic acid and arginine based poly(ester amide)s as the delivery vehicles for improved photodynamic therapy of multidrug resistant tumor cells: An in vitro study of the performance of chlorin e6 photosensitizer.
Ji Y; Zhao J; Chu CC
J Biomed Mater Res A; 2017 May; 105(5):1487-1499. PubMed ID: 27997760
[TBL] [Abstract] [Full Text] [Related]
12. Characteristics of cultured desmoid cells with different ctnnb1 mutation status.
Hamada S; Urakawa H; Kozawa E; Arai E; Ikuta K; Sakai T; Ishiguro N; Nishida Y
Cancer Med; 2016 Feb; 5(2):352-60. PubMed ID: 26686699
[TBL] [Abstract] [Full Text] [Related]
13. Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.
Uitdehaag JC; de Roos JA; van Doornmalen AM; Prinsen MB; Spijkers-Hagelstein JA; de Vetter JR; de Man J; Buijsman RC; Zaman GJ
PLoS One; 2015; 10(5):e0125021. PubMed ID: 26018524
[TBL] [Abstract] [Full Text] [Related]
14. Trans-scleral local resection of toxic choroidal melanoma after proton beam radiotherapy.
Konstantinidis L; Groenewald C; Coupland SE; Damato B
Br J Ophthalmol; 2014 Jun; 98(6):775-9. PubMed ID: 24568869
[TBL] [Abstract] [Full Text] [Related]
15. Pilomatricoma: an unusual dermatologic neoplasm.
DeRosa DC; Lin-Hurtubise K
Hawaii J Med Public Health; 2012 Oct; 71(10):282-6. PubMed ID: 23115748
[TBL] [Abstract] [Full Text] [Related]
16. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
Lovly CM; Dahlman KB; Fohn LE; Su Z; Dias-Santagata D; Hicks DJ; Hucks D; Berry E; Terry C; Duke M; Su Y; Sobolik-Delmaire T; Richmond A; Kelley MC; Vnencak-Jones CL; Iafrate AJ; Sosman J; Pao W
PLoS One; 2012; 7(4):e35309. PubMed ID: 22536370
[TBL] [Abstract] [Full Text] [Related]
17. Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.
Vergani E; Vallacchi V; Frigerio S; Deho P; Mondellini P; Perego P; Cassinelli G; Lanzi C; Testi MA; Rivoltini L; Bongarzone I; Rodolfo M
Neoplasia; 2011 Dec; 13(12):1132-42. PubMed ID: 22241959
[TBL] [Abstract] [Full Text] [Related]
